Zhuhai Rundu Pharmaceutical (002923.SZ) has received the registration certificate for sodium diclofenac sustained-release tablets.

Zhuhai Rundu Pharmaceutical (002923.SZ) announced that the company has recently received two "Drug Registration Certificates" for sustained-release sodium diclofenac tablets (specifications of 100mg and 75mg) issued by the National Medical Products Administration. It is reported that sustained-release sodium diclofenac tablets are suitable for relieving acute episodes or persistent joint swelling and pain symptoms of various chronic arthritis, such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis, and rheumatic arthritis; various soft tissue rheumatic pains, such as shoulder pain, tenosynovitis, bursitis, muscle pain, and post-exercise injury pain; acute mild to moderate pain, such as post-operative, trauma, overuse injuries, primary dysmenorrhea, toothache, headache, etc.